Gennex Laboratories Ltd
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
- Market Cap ₹ 366 Cr.
- Current Price ₹ 16.1
- High / Low ₹ 21.9 / 5.92
- Stock P/E 34.1
- Book Value ₹ 4.88
- Dividend Yield 0.00 %
- ROCE 10.8 %
- ROE 7.86 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 42.5% CAGR over last 5 years
- Company's working capital requirements have reduced from 110 days to 28.7 days
Cons
- Stock is trading at 3.29 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.18%
- The company has delivered a poor sales growth of 8.43% over past five years.
- Promoter holding is low: 18.4%
- Company has a low return on equity of 9.27% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|
42 | 44 | 56 | 56 | 60 | 61 | 66 | 77 | |
37 | 42 | 52 | 52 | 53 | 56 | 61 | 58 | |
Operating Profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 19 |
OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 25% |
0 | 1 | 1 | 1 | 0 | 1 | 4 | 0 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
Profit before tax | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 14 |
Tax % | 13% | 42% | 26% | 27% | 20% | 23% | 23% | |
3 | 1 | 2 | 2 | 4 | 4 | 5 | 11 | |
EPS in Rs | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.61 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 6% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 43% |
3 Years: | 40% |
TTM: | 171% |
Stock Price CAGR | |
---|---|
10 Years: | 34% |
5 Years: | 42% |
3 Years: | 37% |
1 Year: | 164% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 9% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 18 |
Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 69 |
4 | 2 | 5 | 5 | 7 | 10 | 1 | 22 | |
14 | 16 | 13 | 16 | 12 | 14 | 51 | 24 | |
Total Liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 132 |
16 | 16 | 16 | 15 | 14 | 14 | 83 | 66 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 |
26 | 28 | 29 | 35 | 38 | 48 | 49 | 66 | |
Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 132 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
-0 | 3 | 2 | -2 | -1 | 12 | 24 | |
-1 | -1 | -1 | -0 | -0 | -2 | -38 | |
1 | -2 | 1 | -0 | 2 | -2 | 21 | |
Net Cash Flow | -0 | 0 | 2 | -2 | 0 | 8 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
Debtor Days | 90 | 87 | 68 | 41 | 55 | 67 | 52 |
Inventory Days | 43 | 31 | 57 | 78 | 50 | 72 | 139 |
Days Payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 |
Cash Conversion Cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 |
Working Capital Days | 106 | 93 | 86 | 119 | 153 | 148 | 29 |
ROCE % | 6% | 11% | 8% | 14% | 12% | 11% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
25 Apr - With reference to the captioned subject above, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the Certificate received from the M/s …
- Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations, 2015 Of Gennex Laboratories Limited For The Year Ended March 31, 2024 25 Apr
- Closure of Trading Window 29 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the quarter and Nine Months Ended December 31, 2023 announced by the Board in its …
- Dr.S.CH. DHARMA RAO Appointed As An Additional Director In The Capacity Of Non-Executive Director Of The Company 14 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2008
from bse
Business Overview:[1][2]
GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants,
Muscle Relaxants, Analgesic and Anti Fungal, etc.